AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22152216 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 38
Study 22152216 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate meal
Number of subjects: 38
Study 19427180 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong Injection (DHI) administered intravenously
Number of subjects: 80
Study 19427180 — intervention group
Group type: COMPARATOR
Intervention: Routine medication (control group)
Number of subjects: 80
Study 16864724 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 988
Study 16864724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 988
Study 12934420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (2 mg/kg) administered 1 min before intubation
Number of subjects: 135
Study 12934420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (2 mg/kg) administered 3 min before intubation
Number of subjects: 135
Study 12934420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (2 mg/kg) administered 5 min before intubation
Number of subjects: 135
Study 12934420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (2 mg/kg) administered 10 min before intubation
Number of subjects: 135
Study 12934420 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 135
Study 11128559 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 45 mg/kg/day b.d.
Number of subjects: 517
Study 11128559 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 40 mg/kg/day t.d.s.
Number of subjects: 517
Study 9129069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir 8 mg/kg/day
Number of subjects: 42
Study 9129069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir 12 mg/kg/day
Number of subjects: 42
Study 9129069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (compassionate use)
Number of subjects: 42
Study 7949548 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone withdrawal (Group 1)
Number of subjects: 28
Study 7949548 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine < 1.7 mg/dl at the time of steroid withdrawal
Number of subjects: 28
Study 3668883 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal stress management training
Number of subjects: 0
Study 3668883 — intervention group
Group type: COMPARATOR
Intervention: GSR biofeedback training (minimally effective treatment control)
Number of subjects: 0
Study 31840339 — intervention group
Group type: EXPERIMENTAL
Intervention: FITNET-NHS treatment
Number of subjects: 16
Study 31840339 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic features analysis
Number of subjects: 16
Study 29989107 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐mm implants (experimental)
Number of subjects: 50
Study 29989107 — intervention group
Group type: COMPARATOR
Intervention: 10‐mm implants with vertical augmentation (control)
Number of subjects: 50
Study 28963315 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced prednisolone schedule
Number of subjects: 144
Study 28963315 — intervention group
Group type: COMPARATOR
Intervention: Current standard therapy
Number of subjects: 144
Study 23545101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine (2,000 mg/50 cc weekly for 6 weeks, maintenance monthly for 1 year)
Number of subjects: 120
Study 23545101 — intervention group
Group type: COMPARATOR
Intervention: 1/3 dose Bacillus Calmette‐Guérin (weekly for 6 weeks, maintenance 3 weekly instillations at 3, 6 and 12 months)
Number of subjects: 120
Study 19553063 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy (BCT) plus individual‐based treatment (IBT)
Number of subjects: 100
Study 19553063 — intervention group
Group type: COMPARATOR
Intervention: Individual‐based treatment (IBT) only
Number of subjects: 100
Study 16423517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulization of salbutamol (0.15mg/kg)
Number of subjects: 79
Study 16423517 — intervention group
Group type: COMPARATOR
Intervention: Puffs of beta 2 agonist (salbutamol 50 microg/kg or terbutaline 125 microg/kg) via spacer
Number of subjects: 79
Study 15269990 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (0.04 microg.kg(‐1).min(‐1) of Lipo‐PGE1 from the beginning of surgery to the end of study)
Number of subjects: 30
Study 15269990 — intervention group
Group type: COMPARATOR
Intervention: Control (no PGE1 given)
Number of subjects: 30
Study 11403976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupron-induced hypogonadism
Number of subjects: 9
Study 11403976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupron plus estradiol
Number of subjects: 9
Study 11403976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupron plus progesterone replacement
Number of subjects: 9
Study 11403976 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PMS
Number of subjects: 9
Study 9264427 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine (6 g/day for 3 days)
Number of subjects: 22
Study 9264427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8353434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ophthalmic solution 0.3%
Number of subjects: 0
Study 8353434 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol ophthalmic solution 0.5%
Number of subjects: 0
Study 3620283 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10(‐11) M
Number of subjects: 40
Study 3620283 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10(‐10) M
Number of subjects: 40
Study 3620283 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10(‐9) M
Number of subjects: 40
Study 3620283 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 31987562 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping® for lateral rotation of the femur and tibia (KT-LRFT)
Number of subjects: 43
Study 31987562 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping® for patellar medialization (KT-PM)
Number of subjects: 43
Study 31987562 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 43
Study 28771070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation (tele-rehab)
Number of subjects: 54
Study 28771070 — intervention group
Group type: COMPARATOR
Intervention: Office-based physical therapy (OBPT)
Number of subjects: 54
Study 27030575 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 2
Study 27030575 — intervention group
Group type: COMPARATOR
Intervention: High-intensity eccentric exercise
Number of subjects: 2
Study 25090804 — intervention group
Group type: EXPERIMENTAL
Intervention: V-Y capsulorraphy
Number of subjects: 88
Study 25090804 — intervention group
Group type: COMPARATOR
Intervention: Pants-over-vest capsulorraphy
Number of subjects: 88
Study 25090804 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (SF-36 total)
Number of subjects: 88
Study 25090804 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (Kitaoka score)
Number of subjects: 88
Study 23321194 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg orally 2 hours before surgery
Number of subjects: 51
Study 23321194 — intervention group
Group type: COMPARATOR
Intervention: Control (no gabapentin)
Number of subjects: 51
Study 20101071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 20101071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18195263 — intervention group
Group type: EXPERIMENTAL
Intervention: [(18)F]fluoro‐l‐dopa uptake in TLE patients
Number of subjects: 12
Study 18195263 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphologic assessment using voxel‐based morphometry in TLE patients
Number of subjects: 12
Study 18195263 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose metabolism assessment in TLE patients
Number of subjects: 12
Study 16168153 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus CBT
Number of subjects: 90
Study 16168153 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 90
Study 12521974 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led secondary prevention clinics
Number of subjects: 1343
Study 10824634 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pirenzepine (0.5 mg intravenous bolus followed by continuous infusion of 0.15 microg/kg/min)
Number of subjects: 17
Study 10824634 — intervention group
Group type: COMPARATOR
Intervention: Transdermal scopolamine treatment
Number of subjects: 17
Study 8863968 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with 0.12% chlorhexidine paste
Number of subjects: 36
Study 8863968 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis using a 13,500 ppm fluoridated pumice
Number of subjects: 36
Study 8863968 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis with pumice only
Number of subjects: 36
Study 8863968 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual adhesive on enamel surfaces
Number of subjects: 36
Study 8420815 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (900 mg/day)
Number of subjects: 15
Study 8420815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 tablets/day)
Number of subjects: 15
Study 8420815 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (900 mg/day) in normal subjects
Number of subjects: 15
Study 3769568 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 3
Study 3769568 — intervention group
Group type: COMPARATOR
Intervention: Bilateral arm venograms
Number of subjects: 3
Study 30307957 — intervention group
Group type: EXPERIMENTAL
Intervention: Customer self-audit based on the CenteringPregnancy® model of prenatal group care
Number of subjects: 185
Study 30307957 — intervention group
Group type: COMPARATOR
Intervention: Individual care (control group)
Number of subjects: 185
Study 27278385 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise group (RG; n=50)
Number of subjects: 150
Study 27278385 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group (WG; n=50)
Number of subjects: 150
Study 27278385 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; n=50)
Number of subjects: 150
Study 24725239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir for 12 weeks
Number of subjects: 865
Study 24725239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 865
Study 24725239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir for 24 weeks
Number of subjects: 865
Study 24725239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 24 weeks
Number of subjects: 865
Study 22689695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS)
Number of subjects: 382
Study 22689695 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 382
Study 22689695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 20875504 — intervention group
Group type: EXPERIMENTAL
Intervention: Action observation treatment (AOT) in addition to conventional physiotherapy
Number of subjects: 60
Study 20875504 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy only (Control group)
Number of subjects: 60
Study 18212199 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high-fat, low-carbohydrate, protein-permitted (VHFLCPP) diet
Number of subjects: 161
Study 18212199 — intervention group
Group type: COMPARATOR
Intervention: Fasting protocol
Number of subjects: 161
Study 15721704 — intervention group
Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser
Number of subjects: 51
Study 15721704 — intervention group
Group type: COMPARATOR
Intervention: Hansatome mechanical microkeratome
Number of subjects: 51
Study 12720616 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler training
Number of subjects: 30
Study 12720616 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbohaler training
Number of subjects: 30
Study 10576300 — intervention group
Group type: EXPERIMENTAL
Intervention: yohimbine
Number of subjects: 36
Study 10576300 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 36
Study 10576300 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 8942687 — intervention group
Group type: COMPARATOR
Intervention: Ayre spatula, Cytobrush, or cotton swab used alone
Number of subjects: 85000
Study 8942687 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended tip spatula, Ayre spatula combined with Cytobrush or cotton swab, or Cervex brush
Number of subjects: 85000
Study 8942687 — intervention group
Group type: COMPARATOR
Intervention: Cytological methods
Number of subjects: 85000
Study 8942687 — intervention group
Group type: COMPARATOR
Intervention: Histological methods
Number of subjects: 85000
Study 1844694 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 1844694 — intervention group
Group type: COMPARATOR
Intervention: Component therapies
Number of subjects: 0
Study 6421143 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental formula (predigested protein-low fat)
Number of subjects: 2
Study 6421143 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric formula (intact protein-standard fat)
Number of subjects: 2
Study 6421143 — intervention group
Group type: COMPARATOR
Intervention: Solid food standard hospital diet
Number of subjects: 2
Study 30696336 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight bearing aerobic exercise and resistance exercise
Number of subjects: 55
Study 30696336 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 55
Study 29261439 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone plus prednisone (arm A)
Number of subjects: 148
Study 29261439 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone plus prednisone with veliparib (arm B)
Number of subjects: 148
Study 29261439 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DNA-damage repair defect (DRD)
Number of subjects: 148
Study 29261439 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with normal PTEN
Number of subjects: 148
Study 29261439 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with normal TP53
Number of subjects: 148
Study 29261439 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with normal PIK3CA
Number of subjects: 148
Study 26906713 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 40 mg and 60 mg
Number of subjects: 0
Study 26906713 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR 30 mg
Number of subjects: 0
Study 26906713 — intervention group
Group type: COMPARATOR
Intervention: Lanreotide Autogel 120 mg
Number of subjects: 0
Study 24777114 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot running
Number of subjects: 21
Study 24777114 — intervention group
Group type: COMPARATOR
Intervention: Shod running
Number of subjects: 21
Study 22750189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 147
Study 22750189 — intervention group
Group type: COMPARATOR
Intervention: Psychodynamic therapy (PDT)
Number of subjects: 147
Study 20681235 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CMG)
Number of subjects: 14
Study 20681235 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 14
Study 18091407 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPI)
Number of subjects: 4162
Study 18091407 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 4162
Study 15598196 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone plus injectable heroin or methadone plus inhalable heroin prescribed over 12 months (heroin maximum 1000 mg per day, methadone maximum 150 mg per day)
Number of subjects: 430
Study 15598196 — intervention group
Group type: COMPARATOR
Intervention: Standard methadone maintenance treatment
Number of subjects: 430
Study 15598196 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (previously participated in abstinence-oriented treatment)
Number of subjects: 430
Study 15598196 — intervention group
Group type: COMPARATOR
Intervention: Methadone treatment (previously participated in abstinence-oriented treatment)
Number of subjects: 430
Study 15598196 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (no experience in abstinence-oriented treatment)
Number of subjects: 430
Study 15598196 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance treatment (no experience in abstinence-oriented treatment)
Number of subjects: 430
Study 12082591 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study 12082591 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 0
Study 11051015 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ESWT (3 x 5000 impulses, no anesthesia)
Number of subjects: 50
Study 11051015 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ESWT (1 x 5000 impulses, intravenous analgesia)
Number of subjects: 50
Study 7792414 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 58
Study 7792414 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 58
Study 2185681 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex rubber catheters
Number of subjects: 84
Study 2185681 — intervention group
Group type: COMPARATOR
Intervention: PVC catheters
Number of subjects: 84
Study 246947 — intervention group
Group type: EXPERIMENTAL
Intervention: Talampicillin hydrochloride
Number of subjects: 9
Study 246947 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 9
Study 246947 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 9
Study 31764387 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (20 Hz)
Number of subjects: 36
Study 31764387 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 36
Study 30665390 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia testing using HemoCue B‐Haemoglobin analyser
Number of subjects: 1323
Study 30665390 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of the term 'anaemia'
Number of subjects: 1323
Study 30665390 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in moderately food insecure households
Number of subjects: 1323
Study 30665390 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adolescence period (10-14 years)
Number of subjects: 1323
Study 28614793 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of CBD
Number of subjects: 9
Study 28614793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 26275928 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF 500ppm F(‐)
Number of subjects: 16
Study 26275928 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF 1450ppm F(‐)
Number of subjects: 16
Study 26275928 — intervention group
Group type: EXPERIMENTAL
Intervention: AlF3 1360ppmF(‐)+chlorhexidine 0.05% (Lacalut aktiv, LA1360)
Number of subjects: 16
Study 26275928 — intervention group
Group type: COMPARATOR
Intervention: 0ppm F(‐) (negative control)
Number of subjects: 16
Study 23365066 — intervention group
Group type: EXPERIMENTAL
Intervention: eTNS 120 Hz
Number of subjects: 50
Study 23365066 — intervention group
Group type: COMPARATOR
Intervention: eTNS 2 Hz
Number of subjects: 50
Study 20452785 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematoma evacuation
Number of subjects: 821
Study 20452785 — intervention group
Group type: EXPERIMENTAL
Intervention: External ventricular drainage (EVD)
Number of subjects: 821
Study 20452785 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurosurgery (general)
Number of subjects: 821
Study 20452785 — intervention group
Group type: COMPARATOR
Intervention: Control (no neurosurgery)
Number of subjects: 821
Study 19517101 — intervention group
Group type: EXPERIMENTAL
Intervention: CPG-DDS plus 1 mg/kg/day artesunate
Number of subjects: 115
Study 19517101 — intervention group
Group type: EXPERIMENTAL
Intervention: CPG-DDS plus 2 mg/kg/day artesunate
Number of subjects: 115
Study 19517101 — intervention group
Group type: EXPERIMENTAL
Intervention: CPG-DDS plus 4 mg/kg/day artesunate
Number of subjects: 115
Study 19517101 — intervention group
Group type: COMPARATOR
Intervention: CPG-DDS alone (2/2.5 mg/kg/day)
Number of subjects: 115
Study 19517101 — intervention group
Group type: EXPERIMENTAL
Intervention: CPG-DDS plus artesunate
Number of subjects: 115
Study 17355738 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment (3 mg/day to 9 mg/day over time)
Number of subjects: 20
Study 17355738 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained on current antipsychotic medication)
Number of subjects: 20
Study 15209317 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate arousal intensity in steep-gradient arousal conditions
Number of subjects: 80
Study 15209317 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of arousal increase
Number of subjects: 80
Study 15209317 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased movement and exertion
Number of subjects: 80
Study 15209317 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' affect
Number of subjects: 80
Study 11682414 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary hyperventilation with oxygen 100% for 2 minutes after 1 minute of oxygen 100% (Group H)
Number of subjects: 30
Study 11682414 — intervention group
Group type: COMPARATOR
Intervention: Preoxygenation with oxygen 100% for 3 minutes (Group P)
Number of subjects: 30
Study 9762777 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic patients with PEF variation >15%
Number of subjects: 38
Study 9762777 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic patients with PEF variation < or =15%
Number of subjects: 38
Study 9762777 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 7523735 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening using prostate specific antigen and digital rectal examination
Number of subjects: 74000
Study 2458686 — intervention group
Group type: EXPERIMENTAL
Intervention: neurolept anesthesia
Number of subjects: 14